Dupilumab
Dupilumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Chronic Obstructive Pulmonary Disease。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
8 项
已进入 III/IV 期
18 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Sanofi
- Université de Sherbrooke
- UMC Utrecht
- University Hospital, Ghent
- Sally E. Wenzel MD
- Prof. Dr. Stephan Weidinger
- Medical University of Vienna
- Centre hospitalier de l'Université de Montréal (CHUM)
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
澳大利亚、加拿大、英国、荷兰、比利时、美国、德国、奥地利、Argentina、中国、法国、Hungary
正在招募患者的 Dupilumab 研究
A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
III 期招募中澳大利亚加拿大英国NCT07309614Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
不适用招募中荷兰NCT07276425Real Life Study of Biologicals in Patients With Severe CRSwNP
不适用招募中比利时NCT05938972Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
IV 期招募中美国NCT04743791The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
不适用招募中美国NCT07612878Molecular Signatures in Inflammatory Skin Disease
不适用招募中德国NCT03358693DETACT sEvere asThmAtiC paTients - a Pilot Study
不适用招募中奥地利NCT07025200Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
不适用招募中加拿大NCT06743581This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization
IV 期招募中美国NCT07587658ADBest TREAT Registry
不适用招募中德国NCT07904546Dupilumab in the Treatment of Pediatric Alopecia Areata
II 期招募中美国NCT05866562SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
不适用招募中荷兰NCT07021495Molecular Signatures of Cutaneous Dupilumab Response
IV 期招募中美国NCT05858619Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE
II 期招募中美国NCT06705387A Non-interventional Observational Study to Assess Long-term Efficacy and Safety of Dupilumab for the Treatment of Patients (>= 12 Years) With Eosinophilic Esophagitis Under Real-world-conditions in Germany
不适用招募中德国NCT06695897Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
III 期招募中美国Argentina加拿大中国NCT05263206Biologics in Chronic Rhinosinusitis With Nasal Polyposis
IV 期招募中美国NCT06824649Immunological Mechanisms Underlying Mucosal IgE Responses
不适用招募中比利时NCT06234761Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
不适用招募中美国NCT06892704Mind and Skin - the Neurocutaneous Axis in Atopic Eczema
不适用招募中英国NCT05790330Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
I 期 / II 期招募中美国NCT06088771A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
III 期招募中中国NCT07754786Dupilumab Therapy in Nephrotic Syndrome in Children
II 期招募中SingaporeNCT07091175A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
III 期招募中美国日本NCT07783425
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。